Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs panretinal photocoagulation in proliferative diabetic retinopathy
jRCT2031200194Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, single-blind trial of brolucizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in best corrected visual acuity (BCVA) at Week 54. Started Jan 2021; status: completed.
02
Drugs
brolucizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on jRCT2031200194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200194.